The value of plasma renin and its inactive precursor, prorenin, were examined as a marker for vasculitis in rheumatoid arthritis (RA). Plasma renin and prorenin rise when the renin-angiotensin system is activated; an isolated increase of prorenin may be a marker for microvascular complications in diabetes meflitus.
Renin, a proteolytic enzyme released by the kidney, is important in blood pressure regulation and homeostasis of extracellular fluid volume. An inactive precursor called prorenin is also present in the circulation. Any condition that decreases the pressure in the afferent glomerular arteriole stimulates the reninangiotensin system-that is, secretion of both renin and prorenin by the kidney. These triggering conditions include a decreased effective circulating volume, renovascular disease, and the vasculopathy of malignant hypertension.'
An increased prorenin concentration without a concomitant rise in the renin concentration has been reported in pregnant women2 3 and in patients with diabetes mellitus complicated by microangiopathy. 4 In diabetes mellitus the kidney might be the source of prorenin because high prorenin concentrations are associated with the presence and the progression of diabetic nephropathy,4 but new evidence suggests excessive local production at extrarenal sites of neovascularisation and microangiopathy, notably in the retinopathic eye.5 6 In view of all this prorenin might be a marker for microangiopathic complications.
Microangiopathy is also an important factor in the pathogenesis of rheumatoid arthritis (RA) tNSAIDs were withdrawn before the clinical study started.
tension, two had a history of proteinuria, and one a history of renal failure that proved to be reversible after withdrawal of non-steroidal anti-inflammatory drugs. Two control patients were treated with diuretics and two with P blockers. No other antihypertensive drugs were used. All but three patients were treated with non-steroidal anti-inflammatory drugs, the exceptions being one patient with vasculitis and two controls.
All drugs thought to interfere with the reninangiotensin system were stopped, including diuretics and 13 blockers (withdrawn four days before the start of the study) and non-steroidal anti-inflammatory drugs (stopped on the first day of the study). During the study paracetamol and codeine were offered as analgesics; other drugs were left unchanged. The study lasted five days. On the first and the fifth days of the study blood pressure was recorded and blood samples were taken after one hour in the supine position. The creatinine clearance and fractional sodium excretion (sodium excretion/creatinine excretion) were determined in the blood samples combined with three consecutive 24 hour urine samples collected during the intervening days.
MEASUREMENTS
Renin concentrations were measured by an enzyme kinetic assay: the samples were adjusted to pH Raisedplasma renin in rheumatoid vasculitis 
Discussion
This study provides evidence for a higher concentration of both renin and prorenin in patients with RA with vasculitis than in patients with RA without this complication. The difference in renin concentrations between patients with vasculitis and control patients with RA was more marked than the difference in prorenin concentrations. The evidence is based on a small number of patients with vasculitis, in whom most confounding influences on the renin concentration could be controlled, and strengthened by similar findings in stored plasma of a greater number of patients with vasculitis, in whom these influences were less well controlled (see 'Addendum').
It was suggested that prorenin might carry the same significance in RA as in diabetes mellitus. In patients with diabetic nephropathy, increases in prorenin concentration are common, and a high prorenin concentration in patients with subclinical nephropathy correlates with progression of the disease.4 The high prorenin concentrations are unexplained; some authors suggest inadequate renal metabolism,10 others suggest excessive local production at sites of neovascularisation and microangiopathy, especially in the eye.6 [11] [12] [13] Increased prorenin concentrations in patients with RA might be a useful marker for microangiopathy in RA.
The findings in patients with diabetes mellitus differ from those in patients with RA, however, in several respects. In the former group no correlation was found between the prorenin and renin concentrations, contrary to the findings in our patients. Moreover, if microangiopathy in RA were associated with increased prorenin concentrations, one would expect the difference between patients with RA and vasculitis and control patients with RA alone to be more marked for prorenin than for renin concentrations. The different findings in patients with RA and in patients with diabetes mellitus suggest a different cause for the increase in prorenin concentrations in these two diseases.
Activation of the renin-antiogensin system in our patients is a possible cause of the current findings; the trigger is usually volume depletion or a cardiovascular or renal disease.' Volume depletion caused by diuretics might account for the increase of (pro)renin on the first day of the study, but then the concentrations should have decreased after the drugs were withdrawn. Cardiovascular and renal disease caused by rheumatoid vasculitis might also explain our findings. Involvement of these organ systems in rheumatoid vasculitis is not rare. Scott et al found cardiac complications in 17 and renal complications in eight of 50 patients with vasculitis (excluding amyloid)'4; and in one of our earlier studies 10 of 18 necropsied patients with vasculitis had affected kidneys. 5 Activation of the renin-angiotensin system might conceivably be the first clinical manifestation of cardiovascular or renal damage.
In summary, the present results show that activation of the renin-angiotensin system occurs in patients with RA with vasculitis, and that the renin concentrations associated with microangiopathy of RA differ from those associated with diabetes mellitus. Whether activation of the renin-angiotensin system is an early sign of cardiac or renal vasculitis remains to be determined.
Addendum
We also studied stored plasma (-20°C) of an additional 40 patients with RA from the outpatient clinic, 21 with and 19 without vasculitis proved by biopsy. None had diabetes mellitus. The clinical data and the plasma had been collected to study the effect of vasculitis on prognosis in RA. Blood had been obtained in a standardised fashion with the patient in a sitting position.
These patients with vasculitis and controls had reasonably comparable clinical characteristics and had had similar antirheumatic treatment. A history of cardiovascular or renal disease-for example, myocardial infarction, glomerulonephritis, was more prevalent in the vasculitis group. This difference was also reflected in the drug treatment: in the group with vasculitis, five patients were being treated with diuretics and three with f3 blockers; in the control group four patients were being treated with diuretics.
The median renin concentration was higher in the patients with vasculitis (25 (range 4-99) mU/l) than in controls (14 (6-59) mU/l; p=004). Three patients with vasculitis had a renin concentration above the normal limit of 61 mU/l. The median prorenin concentration was slightly but not significantly higher in the patients with vasculitis (138 (35-516) mU/l) than in the controls (115 (39-287) mU/l). Two patients with vasculitis had a prorenin concentration above the normal limit of 358 mU/l. Renin and prorenin concentrations were normal in all control patients.
Although confounding factors such as drug treatment cannot be ruled out, these results support the findings in the main study.
